Literature DB >> 30769370

Intraindividual comparison of selective intraarterial versus systemic intravenous 68Ga-DOTATATE PET/CT in patients with inoperable meningioma.

Frederik A Verburg1,2, Martin Wiessmann3, Georg Neuloh4, Felix M Mottaghy1,5, Marc-Alexander Brockmann3,6.   

Abstract

AIM: Here we describe the results of superselective intraarterial application of diagnostic Ga-68-DOTA0,Tyr3-octreotate (Ga-68-DOTATATE) in a series of patients with inoperable WHO grade II meningiomas which were no longer amenable to radiotherapy.
METHODS: Four patients with inoperable WHO grade II meningioma underwent systemic venous infusion of Ga-68-DOTATATE followed by PET/CT. Ga-68-DOTATATE application was repeated intraarterially via transfemoral catheterization of vessels supplying the meningioma and another PET/CT was performed.
RESULTS: Selective arterial infusion of Ga-68-DOTATATE increased the median value for the maximum standardized uptake value (SUV) by 2.6-fold (median venous: 7.1, median arterial: 21.6; range 2.0-5.0) and the median value for mean SUV by 2.7-fold (median venous: 4.3, median arterial: 11.2; range 1.6-5.6) compared to systemic intravenous infusion. Arterial application was well tolerated by all patients without complications. When compared to liver uptake, intravenous tracer uptake was insufficient for PRRT, whereas tracer uptake after superselective intraarterial tracer injection was sufficient to allow for peptide receptor radionuclide therapy (PRRT) in all patients.
CONCLUSION: Insufficient tracer uptake in meningiomas after intravenous application of Ga-68-DOTATATE may be safely increased by a factor of 2-5 using transfemoral selective intraarterial tracer application. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30769370     DOI: 10.1055/a-0802-5039

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  6 in total

Review 1.  Radiotheranostics: a roadmap for future development.

Authors:  Ken Herrmann; Markus Schwaiger; Jason S Lewis; Stephen B Solomon; Barbara J McNeil; Michael Baumann; Sanjiv S Gambhir; Hedvig Hricak; Ralph Weissleder
Journal:  Lancet Oncol       Date:  2020-03       Impact factor: 41.316

Review 2.  The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas.

Authors:  Christina-Katharina Fodi; Jens Schittenhelm; Jürgen Honegger; Salvador Guillermo Castaneda-Vega; Felix Behling
Journal:  J Clin Med       Date:  2022-04-23       Impact factor: 4.964

Review 3.  The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors.

Authors:  Ilanah J Pruis; Guus A M S van Dongen; Sophie E M Veldhuijzen van Zanten
Journal:  Int J Mol Sci       Date:  2020-02-04       Impact factor: 5.923

Review 4.  The Role of [68Ga]Ga-DOTA-SSTR PET Radiotracers in Brain Tumors: A Systematic Review of the Literature and Ongoing Clinical Trials.

Authors:  Paolo Palmisciano; Gina Watanabe; Andie Conching; Christian Ogasawara; Gianluca Ferini; Othman Bin-Alamer; Ali S Haider; Maria Gabriella Sabini; Giacomo Cuttone; Sebastiano Cosentino; Massimo Ippolito; Giuseppe E Umana
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

Review 5.  Somatostatin Receptor Targeted PET-Imaging for Diagnosis, Radiotherapy Planning and Theranostics of Meningiomas: A Systematic Review of the Literature.

Authors:  Luca Filippi; Isabella Palumbo; Oreste Bagni; Orazio Schillaci; Cynthia Aristei; Barbara Palumbo
Journal:  Diagnostics (Basel)       Date:  2022-07-08

6.  Intraarterial Administration Boosts 177Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients.

Authors:  Evert-Jan P A Vonken; Rutger C G Bruijnen; Tom J Snijders; Tatjana Seute; Marnix G E H Lam; Bart de Keizer; Arthur J A T Braat
Journal:  J Nucl Med       Date:  2021-07-22       Impact factor: 10.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.